Fluphenazine enanthate
Suppliers
Names
[ CAS No. ]:
2746-81-8
[ Name ]:
Fluphenazine enanthate
[Synonym ]:
Fluphenazine enantate
2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyl heptanoate
Fluphenazinenanthat
Fluphenanzin-aenanthat
2-[4-[3-[2-(Trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl heptanoate
Fluphenazin-aenanthsaeureester
4-<3-<2-Trifluormethyl-phenothiazinyl-(10)>-propyl>-1-(2-hydroxy-ethyl)-piperazin-heptanoat
1-heptanoyloxy-2-{4-[3-(2-trifluoromethyl-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethane
Moditen-retard
Prolixin Enanthate
fluphenazine enanthate
fluphenazine O-enantate
Eutimox
EINECS 220-385-0
Chemical & Physical Properties
[ Density]:
1.181g/cm3
[ Boiling Point ]:
629.4ºC at 760mmHg
[ Molecular Formula ]:
C29H38F3N3O2S
[ Molecular Weight ]:
549.69100
[ Flash Point ]:
334.4ºC
[ Exact Mass ]:
549.26400
[ PSA ]:
61.32000
[ LogP ]:
6.77020
[ Vapour Pressure ]:
9.41E-16mmHg at 25°C
[ Index of Refraction ]:
1.544
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- MJ2450000
- CHEMICAL NAME :
- Heptanoic acid, 2-(4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl )- 1-piperazinyl)ethyl ester
- CAS REGISTRY NUMBER :
- 2746-81-8
- LAST UPDATED :
- 199612
- DATA ITEMS CITED :
- 7
- MOLECULAR FORMULA :
- C29-H38-F3-N3-O2-S
- MOLECULAR WEIGHT :
- 549.76
- WISWESSER LINE NOTATION :
- T C666 BN ISJ EXFFF B3- AT6N DNTJ D2OV6
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Human
- DOSE/DURATION :
- 357 ug/kg
- TOXIC EFFECTS :
- Behavioral - muscle weakness
- REFERENCE :
- AJPSAO American Journal of Psychiatry. (American Psychiatric Assoc., Circulation Dept., 1400 K St., NW, Washington, DC 20005) V.78- 1921- Volume(issue)/page/year: 119,779,1963
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- SPECIES OBSERVED :
- Human
- DOSE/DURATION :
- 1633 ug/kg
- TOXIC EFFECTS :
- Musculoskeletal - other changes
- REFERENCE :
- BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 2,1071,1966
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 300 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,701,1982
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 50 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,701,1982
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 56 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- CSLNX* U.S. Army Armament Research & Development Command, Chemical Systems Laboratory, NIOSH Exchange Chemicals. (Aberdeen Proving Ground, MD 21010) Volume(issue)/page/year: NX#03337
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intramuscular
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 17200 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,701,1982 *** REVIEWS *** TOXICOLOGY REVIEW ABPYBL Advances in Biochemical Psychopharmacology. (Raven Press, 1185 Ave. of the Americas, New York, NY 10036) V.1- 1969- Volume(issue)/page/year: 9,301,1974
Safety Information
[ RIDADR ]:
UN 3249
[ Packaging Group ]:
III
[ Hazard Class ]:
6.1(b)
Articles
Int. Clin. Psychopharmacol. 28(5) , 261-6, (2013)
Long-term follow-up data of patients with schizophrenia on depot antipsychotics have been few and the longest follow-up period has been up to 7 years. We carried out a systematic chart review to exami...
Schizophr. Res. 119(1-3) , 153-9, (2010)
This study aimed to characterize the inpatient utilization of depot antipsychotics.The characteristics of adults with schizophrenia or schizoaffective disorder, hospitalized for at least 28 days, and ...
Acta Paediatr. Scand. 71(2) , 335-8, (1982)
A boy was born with a short sloping forehead, wide metopic suture, persistent metopic fontanelle, telecanthus, ocular hypertelorism, nystagmoid eye movements, bilateral cleft lip and palate, imperfora...